VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH MDS 2021 | Immune dysregulation and drug selection in MDS

Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the ‘immunological mess’, or immune dysregulation, associated with myelodysplastic syndromes (MDS) at ESH MDS 2021. Dr Kordasti describes how inflammatory and cellular responses vary between patients, making drug selection challenging. Furthermore, he highlights the need to develop a system of stratifying and selecting MDS patients to optimize drug selection. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter